Tesamorelin Side Effects: FDA Label for Egrifta and Off-Label Use Risks
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue. The branded product Egrifta is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Marketed off-label for general body composition and anti-aging, those uses are not FDA-approved. The FDA prescribing information lists specific side effects, contraindications, and warnings for the approved indication.
Tesamorelin is approved in some jurisdictions but not in others. Egrifta (tesamorelin) is FDA-approved for HIV-associated abdominal lipodystrophy only. Anti-aging, body composition, and athletic use are not FDA-approved indications and are off-label. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- Tesamorelin (Egrifta) is FDA-approved only for HIV-associated abdominal lipodystrophy. Anti-aging and body composition use are off-label.
- Most common adverse reactions per the FDA label: injection-site reactions, arthralgia, peripheral oedema, hypersensitivity.
- Labelled warnings include fluid retention, glucose intolerance / new-onset diabetes, and contraindication in active malignancy.
- Tesamorelin raises IGF-1 levels via pituitary GH release. The FDA label highlights monitoring for glucose tolerance and any malignancy concern.
What is Tesamorelin, and what is it marketed for?
Tesamorelin (Egrifta). Tesamorelin is a synthetic GHRH analogue with a trans-3-hexenoyl group at the N-terminus, which extends the half-life relative to native GHRH. According to the FDA label for Egrifta, it stimulates the pituitary to release growth hormone, which raises IGF-1 levels. Approved use is restricted to the lipodystrophy indication. Effects in other populations are not characterised by FDA-supported trials.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Hypersensitivity reactions | Rash, urticaria, anaphylaxis | Labelled per FDA prescribing information |
| Glucose intolerance / diabetes | Increased blood glucose, new-onset diabetes reported in trials | FDA label warning |
| Fluid retention | Peripheral oedema, joint pain, carpal tunnel syndrome | Common to GH-axis stimulation per the FDA label |
| Injection-site reactions | Erythema, pruritus, pain, irritation, swelling, haemorrhage | Listed in the FDA label as the most common adverse reactions |
| IGF-1 elevation / theoretical neoplasia risk | Tesamorelin raises IGF-1; theoretical concern with active malignancy | FDA label contraindicates use in active malignancy |
| Off-label use | Use outside the approved lipodystrophy indication is uncharacterised by FDA-supported safety data | Not an FDA-approved use |
Taking Tesamorelin alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About Tesamorelin
Yes, under the brand name Egrifta, for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Off-label use for anti-aging or body composition in healthy adults is not an FDA-approved indication.
Per the FDA prescribing information for Egrifta, the most common adverse reactions in trials were arthralgia (joint pain), pain in extremity, peripheral oedema, myalgia, paraesthesia, nausea, vomiting, and injection-site reactions including erythema, pruritus, and irritation.
The FDA label warns about hypersensitivity reactions, fluid retention, glucose intolerance and new-onset diabetes, increased IGF-1 levels, and contraindication in active malignancy and in patients with disrupted hypothalamic-pituitary axis. It also lists pregnancy as a contraindication.
Anti-aging is not an FDA-approved use of tesamorelin. The approved indication is HIV-associated lipodystrophy. Off-label use is not characterised by FDA-supported safety data and should be discussed with a qualified clinician.
References
- U.S. Food & Drug Administration. Egrifta (tesamorelin) prescribing information. Source.
- Falutz J et al. Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients with lipodystrophy. N Engl J Med. 2007;357:2359-2370. Source.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.